Avenue therapeutics announces reverse stock split

Miami, april 24, 2024 (globe newswire) -- avenue therapeutics, inc. (nasdaq: atxi) (“avenue” or the “company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will effect a 1-for-75 reverse split of its issued and outstanding common stock. avenue expects its common stock to begin trading on a split-adjusted basis on the nasdaq capital market as of the commencement of trading on april 26, 2024 with a new cusip number of 05360l403. the ticker symbol for the company's stock will remain “atxi.”
ATXI Ratings Summary
ATXI Quant Ranking